ArticleGynecologic oncology2021
Immunohistochemical biomarkers are prognostic relevant in addition to the ESMO-ESGO-ESTRO risk classification in endometrial cancer.
S W Vrede et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
17 papers cite it
this papercites it